

Human IL-33 (2-270) Protein, His Tag

Catalog # IL3-H51H3



BIOSYSTEMS
Acro

Synonyms

IL33, DV27, C9ORF26, IL1F11, NFHEV, DKFZp586H0523, DVS27, NFEHEV, RP11-575C20.2

Source

Human IL-33 (2-270) Protein, His Tag (IL3-H51H3) is expressed from *E. coli* cells. It contains AA Lys 2 - Thr 270 (Accession # [O95760-1](#)).

Predicted N-terminus: Met

Molecular Characterization

IL-33(Lys 2 - Thr 270)
O95760-1

Poly-his

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 32.6 kDa. The protein migrates as 8 kDa, 29 kDa and 33-35 kDa when calibrated against [Star Ribbon Pre-stained Protein Marker](#) under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per µg by the LAL method / rFC method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Supplied as 0.2 µm filtered solution in PBS, Arginine, pH7.4 with glycerol as protectant.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Please avoid repeated freeze-thaw cycles.


This product is stable after storage at:

- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 12 months under sterile conditions.

ACRO Quality Management System


- [QMS\(ISO, GMP\)](#)
- [Quality Advantages](#)
- [Quality Control Process](#)

SDS-PAGE



Human IL-33 (2-270) Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With [Star Ribbon Pre-stained Protein Marker](#)).

Bioactivity-ELISA



Immobilized Human IL-1RL1, Fc Tag (Cat. No. IL1-H5250) at 5 µg/mL (100 µL/well) can bind Human IL-33 (2-270) Protein, His Tag (Cat. No. IL3-H51H3) with a linear range of 0.01-0.625 µg/mL (QC tested).

Background

Interleukin 33 (IL33) is known as C9orf26, DKFZp586H0523, DVS27, NF-HEV, NFEHEV, RP11-575C20.2, and is a cytokine belonging to the IL-1 superfamily. IL-33 induces helper T cells, mast cells, eosinophils and basophils to produce type 2 cytokines. IL-33 mediates its biological effects by interacting with the receptors ST2 (aka IL1RL1) and IL-1 Receptor Accessory Protein (IL1RAP), activating intracellular molecules in the NF-κB and MAP kinase signaling pathways that drive production of type 2 cytokines (e.g. IL-5 and IL-13) from polarized Th2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs.



www.acrobiosystems.com